Hospital
Prisma Health-Upstate
Prisma Health-Upstate was paid $86.91M by Medicaid between Jan 2018 and Dec 2024, across 574 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 8.4% of everything it billed.
33Billing provider infoPRISMA HEALTH-UPSTATE
GREENVILLE, SC 29605
GREENVILLE, SC 29605
33aNPI1649726738assigned 08/29/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$86.91M
24GClaims2,761,731
24DCodes billed574
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#3 of 115
Median peer was paid$2.47M
This provider vs. median35×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MILLER, POLLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 347,628 | $11.80M | |
| 2019 | 399,519 | $11.19M | |
| 2020 | 404,283 | $11.61M | |
| 2021 | 475,504 | $15.81M | |
| 2022 | 456,685 | $14.81M | |
| 2023 | 372,540 | $12.46M | |
| 2024incomplete | 305,572 | $9.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 8.4% | 105,844 | 91,373 | $7.30M |
| 36415 | Collection of venous blood by venipuncture | 7.5% | 71,607 | 52,144 | $6.50M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.5% | 93,539 | 86,459 | $5.64M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 4.9% | 3,850 | 3,650 | $4.30M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.8% | 28,544 | 26,788 | $4.13M |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.1% | 56,818 | 43,064 | $3.53M |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 3.3% | 1,633 | 1,591 | $2.91M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 3.1% | 4,623 | 4,504 | $2.70M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.9% | 40,798 | 29,574 | $2.48M |
| 86850 | 2.1% | 17,522 | 16,084 | $1.82M | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.0% | 16,459 | 15,526 | $1.77M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.9% | 15,580 | 14,619 | $1.68M |
562 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 20,780 | $1.59M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 34,066 | $1.54M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 33,138 | $1.46M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.6% | 9,989 | $1.41M |
| 81025 | 1.6% | 24,398 | $1.39M | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 16,495 | $1.31M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 24,745 | $1.26M |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 54,677 | $1.01M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.2% | 6,533 | $1.01M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 11,761 | $945K |
| 99284 | Emergency room visit (serious) | 1.0% | 55,364 | $912K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.0% | 20,761 | $891K |
| 93041 | <1% | 2,825 | $705K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,205 | $673K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,751 | $664K |
| 72141 | <1% | 910 | $659K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13,133 | $654K |
| 81001 | <1% | 54,531 | $599K | |
| 87081 | <1% | 27,849 | $593K | |
| 81003 | <1% | 18,283 | $552K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,871 | $531K |
| 87077 | <1% | 20,770 | $529K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 15,304 | $522K |
| 99285 | Emergency room visit (most serious) | <1% | 60,497 | $518K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 24,145 | $495K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,987 | $471K |
| 87070 | <1% | 10,535 | $422K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 10,590 | $405K |
| 76870 | <1% | 1,548 | $403K | |
| 76775 | <1% | 4,097 | $390K | |
| 85610 | <1% | 20,875 | $378K | |
| 74018 | <1% | 6,521 | $364K | |
| 76770 | <1% | 2,959 | $353K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,849 | $330K |
| 71045 | Radiologic examination, chest; single view | <1% | 27,865 | $325K |
| 86900 | <1% | 18,139 | $321K | |
| 83986 | <1% | 1,440 | $319K | |
| 82565 | <1% | 1,797 | $309K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,399 | $309K |
| G0378 | Hospital observation service, per hour | <1% | 40,342 | $304K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 9,699 | $298K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 17,646 | $298K |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 1,732 | $290K |
| 51600 | <1% | 939 | $285K | |
| 76885 | <1% | 1,974 | $278K | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 1,067 | $267K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,958 | $244K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,850 | $228K |
| 74019 | <1% | 3,571 | $223K | |
| 31575 | <1% | 570 | $217K | |
| 76000 | <1% | 4,143 | $209K | |
| 74230 | <1% | 1,843 | $204K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 9,021 | $199K |
| 73080 | <1% | 2,032 | $196K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,185 | $189K |
| 80047 | <1% | 2,424 | $189K | |
| 73090 | <1% | 2,409 | $186K | |
| 87486 | <1% | 2,173 | $183K | |
| 88300 | <1% | 1,704 | $179K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 10,239 | $174K |
| 88307 | <1% | 1,985 | $171K | |
| 99152 | <1% | 4,404 | $168K | |
| 73130 | <1% | 2,466 | $162K | |
| 88304 | <1% | 2,981 | $162K | |
| T1001 | Nursing assessment / evaluation | <1% | 929 | $158K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,522 | $156K |
| 83655 | <1% | 10,080 | $156K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,609 | $151K |
| 84702 | <1% | 8,685 | $149K | |
| 86140 | <1% | 18,472 | $143K | |
| 80061 | Lipid panel | <1% | 21,523 | $139K |
| 12011 | <1% | 1,429 | $137K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 115,183 | $135K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14,583 | $130K |
| 73110 | <1% | 2,369 | $130K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 398 | $127K |
| 12001 | <1% | 1,136 | $127K | |
| 74022 | <1% | 3,713 | $118K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,051 | $116K |
| 73030 | <1% | 2,742 | $115K | |
| 76536 | <1% | 1,124 | $115K | |
| 96376 | <1% | 14,504 | $113K | |
| 93971 | <1% | 1,410 | $111K | |
| 76937 | <1% | 2,965 | $111K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13,809 | $110K |
| 73610 | <1% | 3,205 | $110K | |
| 73590 | <1% | 2,743 | $109K | |
| 73630 | <1% | 2,879 | $105K | |
| 80076 | <1% | 8,806 | $105K | |
| 96367 | <1% | 2,890 | $101K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,304 | $101K |
| 86780 | <1% | 8,956 | $100K | |
| 72146 | <1% | 418 | $98K | |
| 94010 | <1% | 250 | $98K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 790 | $96K |
| 85027 | <1% | 51,099 | $94K | |
| 73564 | <1% | 3,030 | $93K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,136 | $85K |
| 95782 | <1% | 95 | $85K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 44,568 | $85K |
| 82728 | <1% | 8,527 | $84K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 43,936 | $83K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 4,391 | $82K |
| 87210 | <1% | 3,313 | $82K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 574 | $82K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 1,379 | $81K |
| C1769 | Guide wire | <1% | 7,048 | $80K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,091 | $79K |
| J3490 | Unclassified drugs | <1% | 39,281 | $76K |
| 87340 | <1% | 7,476 | $74K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 30,501 | $72K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,038 | $69K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 9,213 | $68K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,201 | $67K |
| 72040 | <1% | 1,687 | $66K | |
| 82950 | <1% | 5,105 | $65K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,952 | $64K |
| 82247 | <1% | 2,601 | $63K | |
| 80074 | <1% | 2,015 | $60K | |
| 73140 | <1% | 477 | $60K | |
| 84484 | <1% | 22,673 | $58K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16,926 | $56K |
| 70250 | <1% | 315 | $52K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 621 | $51K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,192 | $50K |
| 87045 | <1% | 1,303 | $49K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,312 | $48K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 40,635 | $47K |
| 82570 | <1% | 8,438 | $47K | |
| 73060 | <1% | 872 | $46K | |
| 82945 | <1% | 613 | $46K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,663 | $46K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 78 | $45K |
| 84439 | <1% | 6,741 | $43K | |
| 85014 | <1% | 5,120 | $43K | |
| 88313 | <1% | 155 | $41K | |
| 86592 | <1% | 1,869 | $39K | |
| 97162 | <1% | 4,461 | $39K | |
| 49083 | <1% | 64 | $39K | |
| 82330 | <1% | 1,726 | $39K | |
| 72100 | <1% | 1,850 | $39K | |
| 25605 | <1% | 107 | $39K | |
| 70486 | <1% | 996 | $37K | |
| 97161 | <1% | 684 | $37K | |
| 85007 | <1% | 13,849 | $36K | |
| 73552 | <1% | 1,559 | $36K | |
| 82043 | <1% | 3,899 | $36K | |
| 70496 | <1% | 1,235 | $35K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 894 | $34K |
| 74455 | <1% | 882 | $34K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 12,989 | $34K |
| 93458 | <1% | 458 | $33K | |
| 82805 | <1% | 1,532 | $32K | |
| 76857 | <1% | 1,438 | $31K | |
| 76882 | <1% | 497 | $30K | |
| 82607 | <1% | 4,761 | $29K | |
| 73560 | <1% | 980 | $28K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,634 | $27K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,757 | $27K |
| 70491 | <1% | 420 | $26K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 34,495 | $26K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 138 | $25K |
| 10060 | <1% | 170 | $25K | |
| 83020 | <1% | 1,734 | $24K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 18,751 | $24K |
| 94060 | <1% | 77 | $24K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 76 | $24K |
| 99502 | <1% | 135 | $24K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 406 | $24K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 117 | $23K |
| 12002 | <1% | 354 | $23K | |
| 70544 | <1% | 132 | $23K | |
| 87807 | <1% | 375 | $22K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,233 | $22K |
| 72170 | <1% | 1,724 | $22K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 742 | $22K |
| 82947 | <1% | 2,794 | $21K | |
| 80069 | <1% | 736 | $20K | |
| 70360 | <1% | 263 | $20K | |
| 82670 | <1% | 431 | $20K | |
| 82550 | <1% | 4,529 | $19K | |
| 89051 | <1% | 1,797 | $18K | |
| 83993 | <1% | 470 | $18K | |
| 73501 | <1% | 892 | $18K | |
| 72197 | <1% | 13 | $18K | |
| 73070 | <1% | 167 | $18K | |
| 93975 | <1% | 870 | $18K | |
| 85018 | <1% | 3,433 | $17K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,771 | $17K |
| 84132 | <1% | 3,625 | $17K | |
| 90686 | <1% | 1,655 | $16K | |
| 36416 | <1% | 3,578 | $16K | |
| 87507 | <1% | 440 | $16K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,615 | $16K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 574 | $16K |
| 84145 | <1% | 4,873 | $16K | |
| 87040 | <1% | 10,221 | $15K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 595 | $15K |
| 82784 | <1% | 1,784 | $15K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 6,526 | $15K |
| 86308 | <1% | 980 | $15K | |
| 84100 | <1% | 10,935 | $15K | |
| 84146 | <1% | 1,258 | $15K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,729 | $15K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 20,876 | $14K |
| 82105 | <1% | 1,377 | $14K | |
| 93308 | <1% | 1,949 | $14K | |
| 97542 | <1% | 367 | $14K | |
| J1815 | Injection, insulin, per 5 units | <1% | 11,341 | $14K |
| 43235 | <1% | 296 | $13K | |
| 88173 | <1% | 260 | $13K | |
| 83001 | <1% | 947 | $13K | |
| 70498 | <1% | 1,162 | $13K | |
| 83735 | <1% | 26,039 | $12K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 16,577 | $12K |
| 86706 | <1% | 1,368 | $12K | |
| 77001 | <1% | 696 | $12K | |
| 86803 | <1% | 7,535 | $12K | |
| 85347 | <1% | 117 | $12K | |
| 93970 | <1% | 139 | $12K | |
| 82803 | <1% | 4,627 | $12K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,325 | $12K |
| 83516 | <1% | 1,327 | $12K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,358 | $12K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 297 | $11K |
| 87205 | <1% | 5,700 | $11K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,454 | $11K |
| 93017 | <1% | 906 | $11K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,995 | $11K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,508 | $11K |
| 42975 | <1% | 234 | $11K | |
| 94664 | <1% | 2,073 | $11K | |
| 86480 | <1% | 622 | $10K | |
| 36600 | <1% | 243 | $10K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,701 | $10K |
| 83880 | <1% | 8,382 | $10K | |
| 83540 | <1% | 7,252 | $10K | |
| 83690 | <1% | 21,634 | $10K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 191 | $9K |
| 84157 | <1% | 727 | $9K | |
| 86038 | <1% | 1,654 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,286 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,212 | $9K |
| 78264 | <1% | 37 | $9K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,529 | $9K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 549 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,325 | $9K |
| 43762 | <1% | 290 | $9K | |
| 92610 | <1% | 734 | $9K | |
| 31622 | <1% | 828 | $9K | |
| 84550 | <1% | 2,859 | $9K | |
| 10061 | <1% | 111 | $8K | |
| 95811 | <1% | 15 | $8K | |
| 82077 | <1% | 6,155 | $8K | |
| 83615 | <1% | 3,577 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,348 | $7K |
| 82272 | <1% | 123 | $7K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,379 | $7K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,366 | $7K |
| 82270 | <1% | 67 | $7K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,040 | $7K |
| 72156 | <1% | 12 | $7K | |
| 59025 | Fetal non-stress test | <1% | 4,443 | $7K |
| 44970 | <1% | 437 | $7K | |
| 97116 | <1% | 1,371 | $7K | |
| 84156 | <1% | 5,887 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,696 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 28,221 | $7K |
| 91010 | <1% | 26 | $7K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 18,382 | $7K |
| 73100 | <1% | 109 | $7K | |
| 93798 | <1% | 122 | $6K | |
| 76377 | <1% | 13 | $6K | |
| 86695 | <1% | 284 | $6K | |
| 82951 | <1% | 579 | $6K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 3,532 | $6K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 4,292 | $6K |
| 73562 | <1% | 193 | $6K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 163 | $6K |
| 82627 | <1% | 100 | $6K | |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | <1% | 254 | $6K |
| 62270 | <1% | 150 | $6K | |
| 88112 | <1% | 158 | $5K | |
| 84295 | <1% | 1,668 | $5K | |
| 80164 | <1% | 1,786 | $5K | |
| 76604 | <1% | 279 | $5K | |
| 31526 | <1% | 528 | $5K | |
| 82962 | <1% | 116 | $5K | |
| 82435 | <1% | 567 | $5K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 333 | $5K |
| 76942 | <1% | 1,185 | $5K | |
| 71250 | <1% | 69 | $5K | |
| 88302 | <1% | 61 | $5K | |
| 36430 | <1% | 1,087 | $5K | |
| 80143 | <1% | 2,265 | $5K | |
| 69210 | <1% | 45 | $5K | |
| 74270 | <1% | 29 | $4K | |
| 01961 | <1% | 38 | $4K | |
| 80177 | <1% | 537 | $4K | |
| 95700 | <1% | 707 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,441 | $4K |
| 87324 | <1% | 212 | $4K | |
| 93976 | <1% | 3,465 | $4K | |
| 87338 | <1% | 134 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,276 | $4K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 5,441 | $4K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 944 | $4K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 4,506 | $4K |
| 74420 | <1% | 138 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,911 | $4K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,283 | $4K |
| 97166 | <1% | 1,086 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,614 | $3K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 39 | $3K |
| 87177 | <1% | 312 | $3K | |
| 86704 | <1% | 321 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,895 | $3K |
| 84402 | <1% | 506 | $3K | |
| 72070 | <1% | 97 | $3K | |
| 85379 | <1% | 4,619 | $3K | |
| 76801 | <1% | 542 | $3K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 1,705 | $3K |
| 83970 | <1% | 1,574 | $3K | |
| 88184 | <1% | 30 | $3K | |
| 51798 | <1% | 1,238 | $3K | |
| 86762 | <1% | 4,960 | $3K | |
| 85384 | <1% | 1,147 | $3K | |
| 87102 | <1% | 284 | $3K | |
| 84403 | <1% | 1,330 | $3K | |
| C9285 | Lidocaine 70 mg/tetracaine 70 mg, per patch | <1% | 909 | $3K |
| 83605 | <1% | 9,854 | $3K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 2,154 | $3K |
| 82150 | <1% | 249 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 677 | $2K |
| 31720 | <1% | 17 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,008 | $2K |
| 95716 | <1% | 216 | $2K | |
| 43248 | <1% | 393 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 6,599 | $2K |
| 73000 | <1% | 26 | $2K | |
| 72158 | <1% | 39 | $2K | |
| 90715 | <1% | 2,614 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,583 | $2K |
| 83520 | <1% | 109 | $2K | |
| 95249 | <1% | 15 | $2K | |
| 86769 | <1% | 200 | $2K | |
| 97165 | <1% | 754 | $2K | |
| 52356 | <1% | 39 | $2K | |
| 0002A | <1% | 50 | $2K | |
| 82533 | <1% | 183 | $2K | |
| 85730 | <1% | 8,822 | $2K | |
| 86580 | <1% | 2,065 | $2K | |
| 86160 | <1% | 274 | $1K | |
| 25600 | <1% | 37 | $1K | |
| 36561 | <1% | 28 | $1K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 19 | $1K |
| Q3014 | Telehealth originating site facility fee | <1% | 280 | $1K |
| 74330 | <1% | 48 | $1K | |
| 51701 | <1% | 418 | $1K | |
| 96368 | <1% | 314 | $1K | |
| 80081 | <1% | 12 | $1K | |
| 82465 | <1% | 221 | $1K | |
| 82785 | <1% | 14 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,874 | $1K |
| 82746 | <1% | 2,609 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 414 | $1K |
| 85652 | <1% | 4,421 | $1K | |
| 86696 | <1% | 393 | $1K | |
| L4386 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 13 | $1K |
| 86738 | <1% | 58 | $1K | |
| 80179 | <1% | 2,004 | $1K | |
| 49591 | <1% | 12 | $1K | |
| 80197 | <1% | 643 | $1K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 4,303 | $986.30 |
| 0001A | <1% | 78 | $981.27 | |
| 84425 | <1% | 472 | $978.55 | |
| 77003 | <1% | 26 | $961.40 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 785 | $884.42 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 881 | $874.92 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,652 | $868.36 |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 30 | $856.19 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 64 | $848.80 |
| 73502 | <1% | 84 | $809.58 | |
| 99156 | <1% | 311 | $807.85 | |
| 87493 | <1% | 137 | $807.12 | |
| 77076 | <1% | 13 | $796.65 | |
| 86902 | <1% | 31 | $769.85 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,281 | $718.37 |
| 83013 | <1% | 13 | $715.05 | |
| 90682 | <1% | 759 | $709.98 | |
| 93320 | <1% | 26 | $704.93 | |
| 84144 | <1% | 51 | $693.56 | |
| 86431 | <1% | 672 | $675.86 | |
| 82977 | <1% | 346 | $647.28 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,334 | $645.62 |
| 82140 | <1% | 1,115 | $638.15 | |
| 0097U | <1% | 14 | $608.98 | |
| 80178 | <1% | 43 | $582.00 | |
| 82010 | <1% | 1,279 | $572.54 | |
| 86787 | <1% | 690 | $566.09 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,630 | $530.10 |
| 88342 | <1% | 1,478 | $517.79 | |
| 73620 | <1% | 26 | $514.68 | |
| 86200 | <1% | 129 | $472.59 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 807 | $466.08 |
| 36591 | <1% | 311 | $461.78 | |
| 86376 | <1% | 392 | $457.11 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,178 | $444.50 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 38 | $444.05 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 303 | $440.58 |
| 86644 | <1% | 13 | $431.99 | |
| 82310 | <1% | 43 | $426.52 | |
| 86901 | <1% | 18,129 | $419.32 | |
| 93325 | <1% | 106 | $401.64 | |
| 87529 | <1% | 12 | $398.09 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 264 | $378.80 |
| 86870 | <1% | 651 | $376.54 | |
| 87186 | <1% | 15,084 | $340.02 | |
| 85651 | <1% | 4,601 | $257.74 | |
| 84481 | <1% | 270 | $256.58 | |
| 90732 | <1% | 193 | $252.49 | |
| 73600 | <1% | 13 | $245.62 | |
| 36410 | <1% | 1,174 | $241.55 | |
| 92250 | <1% | 14 | $238.63 | |
| 86255 | <1% | 758 | $203.96 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,952 | $199.02 |
| 0004A | <1% | 49 | $196.34 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 158 | $183.12 |
| 83519 | <1% | 50 | $179.31 | |
| 86923 | <1% | 896 | $172.74 | |
| 82438 | <1% | 27 | $142.82 | |
| 83721 | <1% | 598 | $142.56 | |
| 82248 | <1% | 3,033 | $136.86 | |
| A4338 | Indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each | <1% | 338 | $120.00 |
| 90662 | <1% | 375 | $118.58 | |
| 85045 | <1% | 4,491 | $115.36 | |
| 86235 | <1% | 74 | $104.76 | |
| 84466 | <1% | 7,052 | $84.88 | |
| 83002 | <1% | 343 | $83.38 | |
| 87581 | <1% | 2,195 | $77.27 | |
| 87634 | <1% | 17 | $69.33 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,053 | $53.45 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 345 | $51.14 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 9,188 | $45.63 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 432 | $41.98 |
| 84460 | <1% | 38 | $41.62 | |
| 84480 | <1% | 27 | $37.66 | |
| 90750 | <1% | 51 | $33.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 491 | $27.77 |
| 87075 | <1% | 1,788 | $27.69 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,487 | $23.43 |
| 86039 | <1% | 38 | $15.11 | |
| 82390 | <1% | 14 | $14.53 | |
| 85385 | <1% | 415 | $10.61 | |
| 84450 | <1% | 12 | $10.03 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,013 | $8.12 |
| 86003 | <1% | 14 | $6.32 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 1,466 | $5.86 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 28 | $5.47 |
| 85660 | <1% | 53 | $4.07 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 63 | $3.02 |
| 97163 | <1% | 13 | $2.09 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 604 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 709 | $0.00 |
| 88341 | 0% | 473 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 203 | $0.00 |
| 94660 | 0% | 220 | $0.00 | |
| 86664 | 0% | 59 | $0.00 | |
| 82952 | 0% | 303 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 254 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 87 | $0.00 |
| D7140 | Extraction, erupted tooth or exposed root | 0% | 16 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 98 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 243 | $0.00 |
| 94760 | 0% | 87 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 493 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 66 | $0.00 |
| 90656 | 0% | 43 | $0.00 | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 0% | 120 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 116 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 211 | $0.00 |
| 87449 | 0% | 257 | $0.00 | |
| 90677 | 0% | 54 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 50 | $0.00 |
| 75710 | 0% | 117 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 29 | $0.00 |
| 87206 | 0% | 40 | $0.00 | |
| 86317 | 0% | 17 | $0.00 | |
| 84134 | 0% | 29 | $0.00 | |
| 88185 | 0% | 31 | $0.00 | |
| 96415 | 0% | 217 | $0.00 | |
| 94644 | 0% | 41 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 61 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 21 | $0.00 |
| 87116 | 0% | 12 | $0.00 | |
| 43259 | 0% | 12 | $0.00 | |
| 86800 | 0% | 26 | $0.00 | |
| 85240 | 0% | 13 | $0.00 | |
| 86920 | 0% | 13 | $0.00 | |
| 86364 | 0% | 12 | $0.00 | |
| C2623 | Catheter, transluminal angioplasty, drug-coated, non-laser | 0% | 14 | $0.00 |
| 90480 | 0% | 13 | $0.00 | |
| 70543 | 0% | 12 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 23 | $0.00 |
| 86225 | 0% | 12 | $0.00 | |
| 88312 | 0% | 586 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 2,284 | $0.00 |
| 85460 | 0% | 13 | $0.00 | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 276 | $0.00 |
| 86665 | 0% | 62 | $0.00 | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | 0% | 18 | $0.00 |
| 87329 | 0% | 16 | $0.00 | |
| 82610 | 0% | 143 | $0.00 | |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 38 | $0.00 |
| 87328 | 0% | 16 | $0.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 471 | $0.00 |
| 77012 | 0% | 14 | $0.00 | |
| 90685 | 0% | 30 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 81 | $0.00 |
| 94729 | 0% | 178 | $0.00 | |
| 95951 | 0% | 212 | $0.00 | |
| 87209 | 0% | 325 | $0.00 | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 84 | $0.00 |
| 90670 | 0% | 42 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 192 | $0.00 |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 0% | 103 | $0.00 |
| 94770 | 0% | 315 | $0.00 | |
| 95812 | 0% | 34 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 172 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 25 | $0.00 |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml | 0% | 154 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 157 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 433 | $0.00 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 14 | $0.00 |
| 95816 | 0% | 14 | $0.00 | |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 100 | $0.00 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | 0% | 25 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 52 | $0.00 |
| 86708 | 0% | 46 | $0.00 | |
| 47562 | 0% | 65 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 281 | $0.00 |
| 87899 | 0% | 38 | $0.00 | |
| C1874 | Stent, coated/covered, with delivery system | 0% | 93 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 42 | $0.00 |
| 85245 | 0% | 13 | $0.00 | |
| 29125 | 0% | 12 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 54 | $0.00 |
| 10005 | 0% | 15 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 109 | $0.00 |
| 84165 | 0% | 13 | $0.00 | |
| 87207 | 0% | 26 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 41 | $0.00 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 12 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 22 | $0.00 |
| 0124A | 0% | 28 | $0.00 | |
| 58661 | 0% | 30 | $0.00 | |
| 87902 | 0% | 12 | $0.00 | |
| 91320 | 0% | 13 | $0.00 | |
| 90461 | 0% | 12 | $0.00 | |
| 85246 | 0% | 13 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 15 | $0.00 |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, POLLY (VP PAYOR STRATEGIES & ALIGNMENT)
| Provider | Location | Paid |
|---|---|---|
| Prisma Health-Midlands | Columbia, SC | $74.58M |
| Prisma Health-Midlands | Columbia, SC | $68.26M |
| Prisma Health-Upstate | Greenville, SC | $25.04M |
| Prisma Health-Upstate | Greenville, SC | $21.98M |
| Prisma Health-Upstate | Greenville, SC | $19.69M |
| Prisma Health-Upstate | Seneca, SC | $15.64M |
| Prisma Health-Midlands | Columbia, SC | $11.77M |
| Prisma Health-Upstate | Greenville, SC | $10.74M |
| Greenville Health Corporation | Greenville, SC | $8.90M |
| Prisma Health-Upstate | Greenville, SC | $8.32M |
| Prisma Health-Upstate | Greenville, SC | $7.45M |
| Prisma Health University Medical Group | Greenville, SC | $7.44M |
| Prisma Health-Midlands | Coulmbia, SC | $7.43M |
| Prisma Health-Midlands | Columbia, SC | $6.88M |
| Prisma Health Tuomey | Sumter, SC | $6.84M |
| Prisma Health-Midlands | Columbia, SC | $6.77M |
| Prisma Health-Upstate | Greenville, SC | $6.37M |
| Prisma Health-Upstate | Greenville, SC | $5.00M |
| Prisma Health-Upstate | Greenville, SC | $4.65M |
| Prisma Health-Midlands | Columbia, SC | $4.63M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.